Frei, Emil

Emil Frei demonstrates that chemotherapy given... 

Emil Frei demonstrates that chemotherapy given after surgical removal of a tumor increases cure rates (adjuvant chemotherapy)... 

After the cancer history with BCG and interferon, all other tumor immunotherapy measures emerged outside the MDACCC. It was combination chemotherapy that continued to receive a disproportionately overwhelming support at the DDT of MDACC and elsewhere. Discoveries made outside the MDACCC (doxorubicin cytosine arabinoside, or cytarabine) received prompt supportive funds to be tested in clinical trials at the DDT of MDACCC, while support for tumor immunotherapy was left way behind. Early efforts at it failed to receive any support from the NCI/NIH at the DM through the entire 1970s. Cancer chemotherapy proved itself to be a remission-inducer modality of treatment, and thus it was supported in full. The pharmaceutical industry started to pay consultation fees to academic physician principal investigators of chemotherapy protocols at academic institutions. Emil Frei HI, the head of the DDT, published in Cancer Research in 1985 his famous paper Curative cancer chemotherapy , appearing after he left M.D. Anderson for Dana-Farber [2287]. 

Fig. 4.2 Pieta executed by Emil Frei and Company, Saint Louis, Missouri, 1924. Chapel of the National Shrine of Our Lady of Prompt Succor, New Orleans, Louisiana...

---